Recruiting NCT04088422
Cell Free DNA in Mature B-cell Lymphoma
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: peripheral blood collection.
- Who it may be relevant to
- Registry conditions: Mature B-Cell Lymphoma. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Prospective, Observational Study on Cell Free DNA Genotyping as a Tool to Inform Mature B-cell Lymphoma Management
Overview
The purpose of this study is to assess whether plasma cell free DNA is an accurate tool that can early and dynamically inform on treatment outcome and an accessible source of tumor DNA to track tumor clonal evolution.
Interventions
- Procedure peripheral blood collection
peripheral blood collection at treatment start, interm PET/CT, end of treatment PET/CT, one-year and two-year follow-up and or progression or relapse
Primary outcome measures
- progression free survival [Time frame: 2-year]
Secondary outcome measures (2)
- overall survival [Time frame: 2-year]
- Complete Response rate [Time frame: 6 weeks after treatment]
Eligibility criteria
Inclusion criteria
- Documented diagnosis of mature B-cell tumor according to WHO 2008 criteria
- 18 years or older
Exclusion criteria
- Chemotherapy before
- Other tumors
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- Ruijin hospital — Shanghai
Identifiers
NCT: NCT04088422 · cfDNA